Aimi Huang
YOU?
Author Swipe
View article: Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma
Extracellular vesicle miRNAs for predicting the efficacy of late-line treatment with anlotinib in patients with lung adenocarcinoma Open
Background Anlotinib is a targeted therapy indicated for some malignancies, including advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for identifying patients who will benefit from this disease remain lacking. …
View article: Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study
Efficacy and safety analysis of anlotinib combined with PD-1 inhibitors in advanced non-small cell lung cancer: a retrospective cohort study Open
Anlotinib combined with PD-1 inhibitors has potentially good efficacy and a tolerated safety profile in the treatment of advanced NSCLC patients.
View article: Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients
Efficacy, safety, and prognostic factors of anlotinib treatment in advanced non-small cell lung cancer patients Open
Objective: This study aimed to evaluate the treatment response, survival profiles, prognostic factors and adverse events of anlotinib in treating advanced non-small cell lung cancer (NSCLC) patients. Materials and Methods: Totally, 158 adv…
View article: Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study
Afatinib 30 mg in the treatment of common and uncommon EGFR-mutated advanced lung adenocarcinomas: a retrospective, single-center, longitudinal study Open
Afatinib at 30 mg/d is associated with a favorable efficacy and tolerability in the treatment of advanced LAD with common and major uncommon EGFR mutations except 20ins. Further large-scale prospective studies are warranted to confirm our …
View article: Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer
Whole-Exome Sequencing on Circulating Tumor Cells Explores Platinum-Drug Resistance Mutations in Advanced Non-small Cell Lung Cancer Open
Circulating tumor cells (CTCs) have important applications in clinical practice on early tumor diagnosis, prognostic prediction, and treatment evaluation. Platinum-based chemotherapy is a fundamental treatment for non-small cell lung cance…
View article: Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma
Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma Open
Osimertinib has a definite curative effect in the treatment of patients with advanced lung adenocarcinoma, and the incidence of adverse reactions is low.
View article: Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR
Efficacy, safety and prognostic factors analysis of first-line icotinib treatment in advanced non-small cell lung cancer patients with mutated EGFR Open
Background: This study aimed to evaluate the efficacy, safety and prognostic factors of icotinib as first-line treatment in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR)-sensitive mutatio…
View article: Epidermal growth factor receptor (<scp>EGFR</scp>)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with <scp>EGFR</scp> sensitive mutation
Epidermal growth factor receptor (<span>EGFR</span>)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with <span>EGFR</span> sensitive mutation Open
This article demonstrates a case of a lung adenocarcinoma patient in stage IV harboring an epidermal growth factor receptor ( EGFR) 19 exon deletion mutation treated with 500 mg/m 2 pemetrexed and 75 mg/m 2 cisplatin on day 1, sequenced wi…